Akeso, Inc. Akeso’s Ivonescimab head-to-head phase III data against pembrolizumab unveiled at WCLC 2024 [Internet]. New York City: PR Newswire; 2024 Sep 8 [cited 2025 Aug]. Available from: https://www.prnewswire.com/news-releases/akesos-ivonescimab-head-to-head-phase-iii-data-against-pembrolizumab-unveiled-at-wclc-2024-302241266.html.]

Liu A. Akeso, Summit’s PD-1 bispecific crushes Merck’s Keytruda in study, signaling potential new standard in lung cancer [Internet]. New York City: FiercePharma; 2024 Sep 8 [cited 2025 Aug 2]. Available from: https://www.fiercepharma.com/pharma/akeso-summit-pd-1-bispecific-crushes-merck-keytruda-new-standard-lung-cancer.]

Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double- blind, phase 3 study in China. Lancet 2025; 405(10481):839-49.

Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 2019; 18(8):585-608.

Summit Therapeutics. Ivonescimab plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutant non-small cell lung cancer after EGFR TKI therapy in global study [Internet]. Miami: Summit Therapeutics; 2025 May 30 [cited 2025 Aug 2]. Available from: https://www.smmttx.com/pressrelease/https-www-smmttx-com-wp-content-uploads-2025-05-2025_pr_0530-_-harmoni-data-_-final-docx-pdf/.]

Brown A, Groenewegen-Lau J. Lab leader, market ascender: China’s rise in biotechnology [Internet]. Berlin: Mercator Institute for China Studies; 2025 Apr 24 [cited 2025 Aug 2]

Tang L.China-to-West pharmaceutical licensing deals surge in 2024 amid innovation push [Internet]. London: Nat Rev Drug Discov; 2025 May 22 [cited 2025 Aug 2]. Available from: https://www.nature.com/articles/d41573-025-00068-0.

Akeso Inc. Akeso Inc. Announces collaboration and license agreement for up to US$ 5 billion with Summit Therapeutics to accelerate global development and commercialization of its breakthrough bispecific antibody, Ivonescimab (PD-1/ VEGF) [Internet]. Zhongshan: Akeso; 2022 Dec 6 [cited 2025 Aug 2]. Available from: https://www.akesobio.com/en/media/akeso-news/20221206/.]

Reuters. Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports [Internet]. London: Reuters; 2025 Jul 3 [cited 2025 Aug 2]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/summit-considers-up-15-billion-partnership-with-astrazeneca-bloomberg-news-2025-07-03/.]

BioNTech. BioNTech to acquire Biotheus to boost oncology strategy [Internet]. Mainz: BioNTech; 2024 Nov 13 [cited 2025 Aug 2]

Adam D.BMS commits up to $11B+ to work with BioNTech on solid tumor bispecific [Internet]. West Des Moines: BioSpace; 2025 Jun 2 [cited 2025 Aug 2]. Available from: https://www.biospace.com/deals/bms-commits-up-to-11b-to-work-with-biontech-on-solid-tumor-bispecific.]

Merck.Merck closes exclusive global license agreement for LM-299, an investigational anti-PD-1/VEGF bispecific antibody [Internet]. Rahway: Merck; 2024 Dec 20 [cited 2025 Aug 2]. Available from: https://www.merck.com/news/merck-closes-exclusive-global-license-agreement-for-lm-299-an-investigational- anti-pd-1-vegf-bispecific-antibody/.]

Pfizer.Pfizer completes licensing agreement with 3SBio [Internet]. New York City: Pfizer; 2025 Jul 24 [cited 2025 Aug 2]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-licensing-agreement-3sbio.]

Tan R, Hua H, Zhou S, Yang Z, Yang C, Huang G, et al. Current landscape of innovative drug development and regulatory support in China. Signal Transduct Target Ther 2025; 10(1):220.

Liu A. China proposes shorter clinical trial reviews in efforts to accelerate drug development [Internet]. Framingham: FierceBiotech; 2025 Jun 16 [cited 2025 Aug 2]

Zhang J, Zhang P, Wang H, Dong R. Changes in early-phase clinical trials in China during 2013-2022: a review. Drugs R D 2024; 24(3):383-90.

Bettelheim A, Goldman M. China’s biotech boom leaves U.S. playing catch-up [Internet]. Washington, DC: Axios; 2025 May 29 [cited 2025 Aug 2]. Available from: https://www.axios.com/2025/05/29/china-biotech-boom-us-drug-trials.]

Tong A, Furlong A. Pharmaceutical dealmaking between China, West on rise [Internet]. New York City: Bloomberg; 2024 Dec 2 [cited 2025 Aug 2]. Available from: https://www.bloomberg.com/news/articles/2024-12-02/big-pharma-s-bet-on-china-biotech-is-a-rare-trade-bright-spot.]

The Economist. It’s not just AI. China’s medicines are surprising the world, too [Internet]. London: The Economist; 2025 Feb 16 [cited 2025 Aug 2]. Available from: https://www.economist.com/business/2025/02/16/its-not-just-ai-chinas-medicines-are-surprising-the-world-too.]

Waldron J.Regeneron pens $2B pact for Hansoh’s potential obesity rival to Lilly’s Zepbound [Internet]. Framingham: FierceBiotech; 2025 Jun 2 [cited 2025 Aug 2]. Available from: https://www.fiercebiotech.com/biotech/ regeneron-pens-2b-pact-hansohs-potential-rival-zepbound.]

Williams SCP. Effective anti-obesity drugs make losing weight a big deal. Engineering 2024; 32:4-6.

Eaton ES. Hengrui licenses GLP-1 trio to US biotech with $400M from Bain, Atlas [Internet]. London: FirstWord Pharma; 2024 May 16 [cited 2025 Aug 2]. Available from: https://firstwordpharma.com/story/5857796.

Argo Biopharma. Shanghai Argo announces multi-program RNAi licenses and strategic collaborations with Novartis [Internet]. Shanghai: Argo Biopharma; 2024 Jan 7 [cited 2025 Aug 2]. Available from: https://www.argobiopharma.com/news/103.html.]